- Home
- HY vs XNCR Comparison
HY vs XNCR Comparison
Compare HY & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HY
- XNCR
- Stock Information
- Founded
- HY 1991
- XNCR 1997
- Country
- HY United States
- XNCR United States
- Employees
- HY N/A
- XNCR N/A
- Industry
- HY Construction/Ag Equipment/Trucks
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- HY Industrials
- XNCR Health Care
- Exchange
- HY Nasdaq
- XNCR Nasdaq
- Market Cap
- HY 710.8M
- XNCR 579.3M
- IPO Year
- HY N/A
- XNCR 2013
- Fundamental
- Price
- HY $42.54
- XNCR $8.42
- Analyst Decision
- HY Strong Buy
- XNCR Buy
- Analyst Count
- HY 1
- XNCR 7
- Target Price
- HY $70.00
- XNCR $27.50
- AVG Volume (30 Days)
- HY 61.0K
- XNCR 763.4K
- Earning Date
- HY 08-05-2025
- XNCR 08-04-2025
- Dividend Yield
- HY 3.38%
- XNCR N/A
- EPS Growth
- HY N/A
- XNCR N/A
- EPS
- HY 5.60
- XNCR N/A
- Revenue
- HY $4,162,100,000.00
- XNCR $127,228,000.00
- Revenue This Year
- HY N/A
- XNCR N/A
- Revenue Next Year
- HY $2.55
- XNCR $28.84
- P/E Ratio
- HY $7.60
- XNCR N/A
- Revenue Growth
- HY N/A
- XNCR N/A
- 52 Week Low
- HY $34.13
- XNCR $7.16
- 52 Week High
- HY $84.44
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- HY 61.68
- XNCR 44.91
- Support Level
- HY $38.82
- XNCR $7.65
- Resistance Level
- HY $42.70
- XNCR $8.57
- Average True Range (ATR)
- HY 1.14
- XNCR 0.50
- MACD
- HY 0.34
- XNCR -0.04
- Stochastic Oscillator
- HY 91.99
- XNCR 34.35
About HY Hyster-Yale Materials Handling Inc.
Hyster Yale Inc designs, engineers, manufactures, sells and services a comprehensive line of lift trucks, attachments, aftermarket parts and technology solutions marketed globally under the Hyster and Yale brand names. The Company has five segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni) and Nuvera Fuel Cells, LLC (Nuvera). Majority of revenue is from Lift Trucks. geographically operates in America, EMEA, JAPIC, maximum revenue from America.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.